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Background
In 2001 Van den Berghe and colleagues reported that 
target ing a blood glucose concentration of 4.4 to 
6.1 mmol/l (80 to 110 mg/dl) in adult patients treated in a 
surgical ICU reduced both morbidity and mortality [1]. 
Th is research had a profound eﬀ ect on the way the 
management of blood glucose in critically ill patients was 
perceived, with widespread recognition that blood glucose 
management could aﬀ ect important patient outcomes. 
Van den Berghe and colleagues’ paper led to a large body 
of research from numerous investigators that produced a 
much better understanding of the issues surrounding the 
control of blood glucose, also highlighting areas where 
additional research and agreement are urgently needed.
Completed and ongoing research has highlighted two 
critically important issues that currently hamper our 
understanding of the best approach to glycemic control 
in critically ill patients. Th e ﬁ rst relates to how blood 
glucose concentration is measured, because inaccurate 
blood glucose measurement adversely eﬀ ects glycemic 
control and may result in direct harm to patients. Th e 
second issue relates to how glycemic control is reported – 
currently this is not standardized, which makes 
comparing the results of much clinical research 
impossible [2-5].
In Van den Berghe and colleagues’ original trial, blood 
glucose concentration was measured using a blood gas 
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analyzer, a method that has been shown to be accurate 
[2]. Subsequent trials have used a variety of methods to 
measure the blood glucose concentration, which have 
included single speciﬁ ed bedside glucose meters [6,7] or 
combined methods using speciﬁ ed or unspeciﬁ ed glucose 
meters and blood gas analyzers variably both within and 
between sites in multicenter trials [8,9]. With increasing 
awareness of the association between hyperglycemia [10], 
hypoglycemia [11], and glucose variability [12] with in-
creased mortality and morbidity has come the realiza tion 
that more accurate measurement of blood glucose 
concentration might be crucial for improving patients’ 
outcomes. Accurate measure ment of the blood glucose 
concentration requires not only the use of accurate 
analyzers but also standardized blood sampling and 
handling. Pre-analytical errors arise due to variable blood 
sampling and handling, and these errors may be larger 
than those arising from the use of inaccurate analyzers.
Point-of-care devices were not designed for ICU use or 
to be used to regulate insulin infusions in critically ill 
patients. Th e ICU is a unique environment where read-
ings from glucose meters may be subject to further in-
accuracies due to rapid changes in hematocrit or oxygena-
tion and interference from medications and other physical 
or chemical factors [13]. In response to these concerns, 
newer glucose meters try to correct known problems  – 
and monitors capable of continuous or automated inter-
mittent measurement of blood glucose are being 
developed speciﬁ cally for use in the ICU.
A further issue is the assessment and reporting of 
glycemic control [3]. Glycemic control can be reported in 
many diﬀ erent ways with a focus on diﬀ erent measures of 
central tendency (mean, median, mode, and so forth) and 
dispersion (standard deviation, range, interquartile 
range). Within these domains the dimension of time also 
has to be considered along with the impact of the fre-
quency with which blood glucose concentration is 
measured. Th is consideration has resulted in glycemic 
control being reported in many diﬀ erent ways, which 
introduces further diﬃ  culty when trying to assess the 
adequacy of glycemic control and to understand and to 
compare the results of the various clinical trials.
In light of the uncertainties in this area we convened a 
meeting of interested parties and experts plus invited 
observers from industry to discuss and where possible 
reach consensus on the most appropriate methods to 
measure and monitor blood glucose in critically ill patients 
and on how glycemic control should be assessed and 
reported. Recognizing their clear conﬂ ict of interest, 
industry observers played no role in developing the con-
sensus or recommendations from the meeting. Where the 
academic participants could not reach consensus, they 
sought to make recommendations on further research and 
data needed to reach consensus in the future.
Th e following issues were addressed: How should we 
measure and report glucose control when intermittent 
blood glucose measurements are used? What are the 
appropriate performance standards for intermittent 
blood glucose monitors in the ICU? Continuous or 
automated intermittent glucose monitoring  – methods 
and technology: can we use the same measures for assess-
ment of glucose control with continuous and intermittent 
monitoring? What is acceptable perfor mance for 
continuous glucose monitoring systems?
How should we measure and report glucose control 
when intermittent blood glucose measurements 
are used?
Glycemic control is commonly reported using measures 
of central tendency and dispersion, and additionally most 
investigators report either the number of patients who 
experience hypoglycemia and/or the number of occasions 
on which hypoglycemia occurs. Some investigators have 
reported the time to attain the target blood glucose and 
the proportion of time blood glucose concentration is 
within the target range. Additionally, a variety of more 
complex measures have been proposed that assess 
elements of glycemic control, such as time and distance 
away from a target range and the degree of variability in 
blood glucose concentration [3,14]. Mackenzie and 
colleagues analyzed data from four adult ICUs in one 
hospital in the UK and concluded that each of the various 
metrics was measuring one of three features of glycemic 
control [3]. Using cluster analysis they classiﬁ ed 13 
reported metrics into two families representing central 
tendency and dispersion, or measures of minimum 
glucose that were related to neither family. Each of these 
three features of glycemic control (central tendency, 
dispersion and minimum glucose) had an association 
with patients’ outcomes (Figure 1).
Th e group then considered the eﬀ ect of measurement 
frequency and duration of monitoring on the various 
measures of glycemic control. With regard to simple 
measures it is clear that all indices may be aﬀ ected by 
frequency of measurement and duration of monitoring. 
For example, a reported mean blood glucose that just 
averages all measurements will be lower in a study that 
mandates frequent measurements around the lower limit 
of normal when compared with another protocol that 
does not. Likewise, diﬀ erent durations of treatment and 
study may produce diﬀ erent summary results as all 
indices tend to improve over 3 to 4 days and then stabilize 
[15].
A further consideration discussed was how summary 
measures for populations of patients should be calculated 
and reported. For example, a mean blood glucose con-
cen tration for a population over time could represent the 
sum of all the blood glucose measures of that population 
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divided by the number of measures. An alternative would 
be to calculate each patient’s mean blood glucose 
concentration (the sum of all that patient’s blood glucose 
measures divided by the number of measures) and then 
report the mean of the individual patients’ mean blood 
glucose concentrations. Th ese might be quite diﬀ erent 
numbers depending on how many measurements each 
patient contributed. Similar considerations apply to other 
measures such as the standard deviation, which may be 
reported as the standard deviation of the individual 
glucose measurement or the standard deviation of the 
indi vidual patient means. Although not commonly re-
ported it is critical that studies explain how such 
summary measures are calculated.
Meeting consensus
Given that many measures are eﬀ ectively reporting 
similar variables, the consensus was that simple measures 
which are intuitively understood should be reported and 
standardized as the appropriate measures of glycemic 
control.
Trials or observational studies should report the following:
1. Central tendency  – for blood glucose concentration 
measurements from a population of patients, the 
median and interquartile range of individual patient 
means should be reported.
2. Dispersion – one should calculate the standard devia-
tion of blood glucose concentration for each patient, 
and then report the median and interquartile range of 
standard deviations for the population.
3. Hypoglycemia  – as a minimum, investigators should 
report the number and percentage of patients experi-
encing at least one episode of severe and moderate 
hypoglycemia. Severe hypoglycemia is deﬁ ned as blood 
glucose concentration ≤2.2  mmol/l (≤40  mg/dl); 
moderate hypo glycemia is deﬁ ned as a blood glucose 
concen tration of 2.3 to 3.9  mmol/l (41 to 70  mg/dl). 
Th e number and percentage of patients experiencing 
hypo glycemia related to insulin treatment (iatrogenic) 
and unrelated to insulin treatment (spontaneous; for 
example, terminal event in patient dying of hepatic 
failure) should be reported separately. Investigators are 
strongly encouraged to report as much detail as possible 
on hypo glycemia events (for instance, dura tion, asso-
ciated symp toms, amount of glucose adminis tered, 
next blood glucose), if necessary in an electronic 
supple ment, as there will be no randomized trials of 
hypo gly cemia and retrospective or registry studies 
often have only sparse information.
Th e recommendation to report the above metrics was a 
pragmatic one, with the group recognizing that further 
research was needed to deﬁ ne the optimal metric in each 
of the domains. Th e optimal metric would be the one with 
the best balance of simplicity and performance in terms of 
association with and prediction of clinical outcome.
In addition to reporting the above metrics, investigators 
should also report the frequency of blood glucose 
measurement, the duration of monitoring, the nature of 
blood sampling (that is, capillary vs. peripheral venous 
vs. central venous vs. arterial sampling) and the tech-
nology used to measure blood glucose.
What are the appropriate performance standards 
for intermittent blood glucose monitors in the ICU?
Measurement of blood glucose concentration in ICUs is 
currently performed almost entirely intermittently, with 
analysis using either point-of-care glucose meters or 
blood gas analyzers. Although accurate data are not 
available, most measurements are probably made on 
glucose meters and the majority of samples are capillary 
blood obtained by ﬁ nger pricks. Th e use of glucose 
meters and sampling capillary blood both have the 
potential to introduce errors into the measurement of 
blood glucose concentration.
Th e accuracy of glucose meters has been the subject of a 
number of studies, with the near-universal conclusion that 
they are not suﬃ  ciently accurate for use in the ICU 
[2,4,5,16]. Current regulatory and consensus guidelines for 
glucose meter accuracy are dated and were developed 
primarily for self-monitoring home-use devices. For 
instance, the current International Standards Organiza tion 
standard (ISO 15197) requires that 95% of results from a 
glucose meter be within 20% (or 15  mg/dl for values 
<75 mg/dl) of results obtained from a reference measure-
ment such as a central laboratory hexokinase method or a 
Yellow Springs Instrument (Yellow Springs Instruments, 
Yellow Springs, OH, USA). Similarly, the Clinical 
Laboratory and Standards Institute (CLSI C30-A2) states 
that 95% of meter values must be within 20% (or 15 mg/dl 
for values <75 mg/dl) of a reference method. In the USA, 
Figure 1. Dendrogram of measures of central tendency, 
dispersion and hypoglycemia. See [3] for a full explanation. 
Reproduced with permission.
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the US Food and Drug Administration has used similar 
criteria to approve glucose meters for marketing. One 
obvious problem with these criteria is that they allow 1 in 
20 (5%) meter readings to diﬀ er by any amount from the 
reference method, which could lead to dangerous changes 
in insulin therapy in critically ill patients.
Furthermore, many current meters are susceptible to 
interferences from reducing substances such as ascorbic 
acid and acetaminophen (paracetamol) and many are still 
aﬀ ected by the patient’s hematocrit [13,17]. Th e eﬀ ect of 
hematocrit is particularly concerning in critical care 
where a patient with a true glucose of 80  mg/dl and a 
hematocrit of 0.25 may have a positive bias of as much as 
18 mg/dl [17]. In addition, meters are subject to operator 
error, which is diﬃ  cult to quantify but occurred in 0.5 to 
0.8% of measurements at one institution [5]. Despite 
being in common use in critical care units, numerous 
modeling studies have shown that current meter pre-
cision and accuracy are inadequate to avoid clinically 
signiﬁ cant errors in insulin dosing that might induce 
hypoglycemia [18,19]. Th ese studies also show that 4 to 
15% of hypoglycemic events may be undetected by 
current meters. Interestingly, these modeling studies all 
suggest that a total analytic error ((2×%Coeﬃ  cient of 
variation) + %Bias) of 10 to 15% will avoid most dosing 
errors and undetected hypoglycemia [18,19].
In 1987 Clarke and colleagues described an error grid 
that could be used to describe the clinical accuracy of 
systems designed for the self-monitoring of blood glucose 
concentration by patients with diabetes and also 
indicated when inaccuracies in the measurement were 
likely to result in treatment errors that were potentially 
dangerous for patients [20]. While the original error grid 
may have fulﬁ lled its initial purpose, its design is based 
on assumptions that limit its value in the management of 
today’s critically ill patients. Th e grid was designed to be 
used with a target range of 70 to 180 mg/dl and assumes 
no change in treatment when readings lie within that 
range. Th e grid assumes that treatment of blood glucose 
concentration outside the target range will be similar to 
that of the patients treated in Clarke’s institution in 1987. 
Furthermore, the grid makes no allowance for the rate at 
which blood glucose concentration is changing or the 
frequency with which the blood glucose concentration is 
being measured [20]. Th e assumptions underlying the 
design of the error grid do not hold true in critically ill 
patients and make the original Clarke and colleagues 
error grid unsuitable for use in critically ill patients. 
While modiﬁ ed error grids have been described, their 
value in critically ill patients is as yet unproven [21].
Alternatives to the use of glucose meters are measure-
ment in the hospital’s central laboratory or using a blood 
gas analyzer in the ICU. Accuracy standards for measure-
ment of blood glucose in hospital laboratories are ±6 mg/
dl (0.33 mmol/l) or 10% (whichever is greater) in the USA 
[22], ±9.4% in the Netherlands [23], and ±0.4 mmol/l (or 
±8% above 5 mmol/l) in Australia [24]. Although central 
laboratory measurement is much more accurate, the time 
delay in sending samples to the laboratory makes this an 
impractical solution for the ICUs in most hospitals. A 
more practical solution, but one that may have con-
siderable cost implications, is to measure the blood 
glucose concentration in a blood gas analyzer because 
the majority of ICUs in the developed world will have 
such an analyzer in the ICU. Measurements from a 
properly maintained blood gas analyzer will have similar 
accuracy to central laboratory measurements [2].
Sampling site
An additional consideration is that the blood glucose 
concentration varies in diﬀ erent vascular beds and the site 
from which blood is sampled can introduce further errors. 
Th e blood glucose concentration in radial arterial blood 
will be approximately 0.2 mmol/l higher than that in blood 
sampled from a peripheral vein, and 0.3 to 0.4  mmol/l 
higher than that in blood sampled from the superior vena 
cava. Sampling capillary blood in ICU patients, particularly 
in those who are hemodynamically unstable and being 
treated with vasopressors, can introduce large errors when 
compared with a reference method in which glucose is 
measured in central venous or arterial samples [2,25].
Th e frequency with which the blood glucose con cen-
tration is measured in the ICU makes venipuncture 
impractical, and viable alternatives are to sample from 
indwelling arterial or venous catheters. Sampling from 
indwelling vascular catheters may increase the risk of 
catheter-related bloodstream infection but this risk has 
not been quantiﬁ ed. Obviously, when sampling from 
indwelling catheters it is essential to avoid contamination 
from infusions of glucose-containing ﬂ uids. Th is caution 
is particularly important with venous catheters, but 
accidental use of 5% glucose in an arterial-line ﬂ ush bag 
has resulted in the death of at least one patient [26]. A 
further potential draw back to sampling from indwelling 
catheters is the discarding of large volumes of blood to 
obtain un contaminated samples. In the case of arterial 
catheters there is also the potential for contamination by 
the ﬂ ush solution if an inadequate volume of dead space 
blood is withdrawn. Th ese concerns can be reduced or 
obviated by using a blood conservation system, but this 
adds to the cost of the procedure.
Recommendations for clinical practice and for conducting 
and reporting clinical trials and observational studies 
(Table 1)
Th ere was general consensus that the current Inter-
national Standards Organization standard that was 
developed speciﬁ cally for home-use meters is not 
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Table 1. Summary of the recommendations
Blood sampling
1. Patients whose severity of illness justifi es invasive vascular monitoring
 a. All blood samples should be drawn from an arterial line
 b. If an arterial line is temporarily or permanently unavailable, sample from a venous line
 c. Capillary (needle stick) samples are inaccurate and should not be used 
2. Patients whose severity of illness does not justify invasive vascular monitoring
 a. Capillary (needle stick) samples may be used
3. Clinical research papers should report the number and percentage of blood samples obtained from arterial catheters, central and peripheral venous 
 catheters and capillary (needle stick) samples
Choice of blood glucose analyzer in clinical research in critical care units
 a. Samples taken from arterial or central venous catheters should be analyzed in a central laboratory or blood gas analyzer; a blood gas analyzer should 
  be the default analyzer
 b. Only when capillary samples are taken from patients without invasive vascular monitoring is analysis using a glucose meter acceptable
 c. Clinical research papers should report the number and percentage of samples analyzed using central laboratory or blood gas analyzers or glucose 
  meters. In all cases, the make and model of the analyzer used should be reported along with routine calibration and quality assurance measures
Reporting glycemic control – trials or observational studies should report
1. Central tendency – for blood glucose concentration measurements from a population of patients, the median and interquartile range of individual patient 
 means should be reported
2. Dispersion – calculate the standard deviation of blood glucose concentration for each patient then report the median and interquartile range of standard 
 deviations for the population
3. Hypoglycemia – as a minimum, investigators should report the number and percentage of patients experiencing at least one episode of severe and 
 moderate hypoglycemia (blood glucose concentration ≤2.2 (≤40 mg/dl) and 2.3 to 3.9 mmol/l (41 to 70 mg/dl) respectively). Report separately the 
 number and percentage of patients experiencing hypoglycemia related to insulin treatment (iatrogenic) and unrelated to insulin treatment (spontaneous)
For severe hypoglycemia, report duration of hypoglycemia, associated symptoms, amount of glucose administered, and next blood glucose concentration
Appropriate standards for intermittent measurement of blood glucose in the ICU
Blood sampling
1. Patients whose severity of illness justifi es invasive vascular monitoring
 a. All blood samples should be drawn from an arterial line
 b. If an arterial line is temporarily or permanently unavailable, sample from a venous line
 c. Capillary (needle stick) samples are inaccurate and should not be used 
2. Patients whose severity of illness does not justify invasive vascular monitoring
 a. Capillary (needle stick) samples may be used
Choice of blood glucose analyzer in clinical practice in critical care units
1. Patients whose severity of illness justifi es invasive vascular monitoring
 a. Samples taken from arterial or central venous catheters should be analyzed in a central laboratory or blood gas analyzer; a blood gas analyzer should 
  be the default analyzer, central laboratory measurements should only be used if results can be obtained without delay
2. Patients whose severity of illness does not justify invasive vascular monitoring
 a. Only when capillary samples are taken from patients considered well to need invasive vascular monitoring is analysis using a glucose meter 
  acceptable
Accuracy of blood glucose analyzers used in clinical practice in critical care units
1. Patients whose severity of illness justifi es invasive vascular monitoring
 a. Central laboratory analyzers and blood gas analyzers in the ICU should perform to currently acceptable international standards (for example, 
  ±0.4 mmol/l (or ±8% above 5 mmol/l))
2. Patients whose severity of illness does not justify invasive vascular monitoring
 a. The minimum standard for glucose meters to be used in critically ill patients should be that 98% of readings are within 12.5% of a reference standard 
  (or within 0.55 mmol/l for readings <5.5 mmol/l). The remaining 2% of readings should be within 20% of a reference standard
Continuous and automated intermittent blood glucose monitoring
Assessment of glycemic control when continuous or automated intermittent blood glucose monitoring used
1. Currently there are few data to guide the choice of appropriate metrics for reporting glycemic control when continuous or automated intermittent blood 
 glucose monitoring is used. There is a need to defi ne measures that are associated with important patient-centered outcomes such as mortality and major 
 morbidity
Comparing glycemic control with continuous versus intermittent measurement of blood glucose 
1. Comparison of the glycemic control achieved with continuous versus intermittent monitoring must be evaluated in randomized controlled trials with both 
 groups of patients having a continuous monitor but the output from the continuous monitor masked in the control group where blood glucose is 
 managed by intermittent monitoring
Continued overleaf
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appropriate for the measurement of the blood glucose 
concentration in critically ill patients and that sampling 
of capillary blood introduces unacceptable errors and 
uncertainty. Th e meeting also recognized that illness 
severity and case mix can vary greatly between individual 
units and countries, and that any recommendations should 
consider these factors. For example, it may be appropriate 
to target moderately tight glucose control in patients in a 
cardiac care unit but such patients would not have 
indwelling arterial catheters or central venous catheters.
Recommendations for clinical practice are as follows:
1. Blood sampling for glucose measurement in critical care:
a. All patients whose severity of illness justiﬁ es the 
presence of invasive vascular monitoring (an in-
dwelling arterial and/or central venous catheter) 
should have all samples for measurement of the 
blood glucose concentration taken from the 
arterial catheter as the ﬁ rst option. If blood 
cannot be sampled from an arterial catheter or an 
arterial catheter is temporarily or permanently 
unavailable, blood may be sampled from a venous 
catheter as a second option; appropriate attention 
must be paid to maintaining sterility and avoiding 
contamination of the sample by ﬂ ush solution.
b. Only when a patient’s severity of illness does not 
justify the presence of invasive vascular monitor-
ing are capillary samples acceptable for the 
measurement of the blood glucose concentration.
2. Choice of blood glucose analyzer in clinical practice in 
critical care units:
a. Samples taken from arterial or central venous 
catheters should be analyzed in a central labora-
tory or blood gas analyzer. For most ICUs the 
delay associated with central laboratory analysis 
will be unacceptable and therefore a blood gas 
analyzer should be the default analyzer.
b. Only when capillary samples are taken from patients 
considered too well to need invasive vascular moni-
toring is analysis using a glucose meter acceptable.
3. Accuracy of blood glucose analyzers used in clinical 
practice in critical care units:
a. Central laboratory analyzers and blood gas 
analyzers in the ICU should perform to currently 
acceptable international standards  – accuracy 
Table 1. Continued
What are desirable performance standards for continuous glucose monitoring systems?
1. Set-up, calibration and integration with standard ICU care
 a. <20 minutes to set by a nurse, technician, or physician
 b. <10 minutes required for initial and subsequent calibration
 c. <20 minutes required for sensor insertion
 d. Calibration against a reference standard to maintain point accuracy is required no more frequently than every 8 hours and preferably no more than 
  twice per 24 hours
 e. CGM requires few nursing interventions per 24 hours to produce a near-continuous datastream
 f. CGM sensor inserted into an arterial or central venous catheter should not adversely aff ect blood sampling or monitoring of cardiovascular system or 
  increase the frequency with which such monitoring lines occlude
 g. Incidence of infection, hematoma, tissue ischemia, and/or thromboembolism should not exceed that which occurs in usual clinical practice in the 
  absence of a CGM
2. Reliability
 a. CGM should continuously measure glucose and display in real time >95% of the time for the duration of time specifi ed in the product label 
  (2 to 7 days)
 b. Skips in data acquisition should not exceed 30 minutes at a time
 c. The CGM should have an internal mechanism that prevents the display or reporting of erroneous or spurious data
3. Point accuracy – this should be the same as for intermittent monitors if the CGM is being used alone to guide clinical management and administration of 
 insulin
 a. 98% of readings are within 12.5% of a reference standard (or within 0.55 mmol/l for readings <5.5 mmol/l). The remaining 2% of readings should be 
  within 20% of a reference standard
 b. CGM sensors inserted in arterial and central venous catheters may transiently indicate false low readings when those catheters are fl ushed with saline 
  or other glucose-free solutions. The CGM should alert the treating clinicians that rapid reductions in the measured blood glucose concentration may 
  be due to fl ushing of the arterial or central venous catheter
 c. CGM sensors inserted in peripheral and central veins may transiently indicate false high readings if venous blood in those veins is contaminated with 
  glucose-containing solutions. The CGM should alert the treating clinicians to rapid increases in the measured blood glucose concentration that may 
  be due to contamination by glucose-containing solutions
4. Rate or trend accuracy – trend metrics have not been tested suffi  ciently to provide defi nitive guidance or recommendations; this is an area for future 
 research
5. Alarms and alerts for hypoglycemia and hyperglycemia alerts
 a. Real-time blood glucose concentration and trend data should be displayed at the bedside; with visual and audible alerts and alarms for hypoglycemia, 
  hyperglycemia, and rapid rates of change
 b. The CGM data should be suffi  ciently frequent, reliable, and accurate for alarm algorithms to detect and/or predict hypoglycemia and hyperglycemia 
  with high sensitivity and specifi city
Recommendations for conducting and reporting clinical trials and observational studies. CGM, continuous or automated intermittent glucose monitoring system.
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standards for measurement of blood glucose in 
hospital laboratories are ±6  mg/dl (0.33  mmol/l) 
or 10% (whichever is greater) in the USA [22], 
±9.4% in the Netherlands [23], and ±0.4  mmol/l 
(or ±8% above 5 mmol/l) in Australia [24].
b. Th e current International Standards Organization 
standard for glucose meters is not appropriate for 
critically ill patients – the minimum standard for 
glucose meters to be used in critically ill patients 
should be that 98% of readings are within 12.5% of 
a reference standard (or within 0.55  mmol/l for 
readings <5.5 mmol/l); the remaining 2% of read-
ings should be within 20% of a reference standard.
Recommendations for conducting and reporting 
clinical trials and observational studies are as follows:
1. Site of blood sampling for glucose measurement in 
clinical research:
a. All patients whose severity of illness justiﬁ es the 
presence of invasive vascular monitoring (an 
indwelling arterial and/or central venous catheter) 
should have all samples for measurement of blood 
glucose concentration taken from the arterial 
catheter as the ﬁ rst option. If blood cannot be 
sampled from an arterial catheter or an arterial 
catheter is temporarily or permanently un avail-
able, blood may be sampled from a venous 
catheter as a second option; appropriate attention 
must be paid to maintaining sterility and avoiding 
contamination of the sample by ﬂ ush solution.
b. Only when a patient’s severity of illness does not 
justify the presence of invasive vascular monitor-
ing are capillary samples acceptable for the 
measurement of blood glucose concentration.
c. Clinical research papers should report the number 
and percentage of blood samples obtained from 
arterial catheters, central and peripheral venous 
catheters and capillary (needle sticks) samples.
2. Choice of blood glucose analyzer in clinical research in 
critical care units:
a. Samples taken from arterial or central venous 
catheters should be analyzed in a central labora-
tory or blood gas analyzer. For most ICUs the 
delay associated with central laboratory analysis 
will be unacceptable and therefore a blood gas 
analyzer should be the default analyzer.
b. Only when capillary samples are taken from 
patients without invasive vascular monitoring is 
analysis using a glucose meter acceptable.
c. Clinical research papers should report the number 
and percentage of samples analyzed using central 
laboratory or blood gas analyzers or glucose 
meters. In all cases, the make and model of the 
analyzer used should be reported along with 
routine calibration and quality assurance measures.
Continuous glucose monitoring – methods and 
technology
More than 30 years of intense academic and commercial 
activity in the development of continuous glucose 
monitoring systems have been focused to a great degree 
on ambulatory measurements in patients with type I 
diabetes. Th e technologies developed to date encompass 
both electrochemical and optical measurement principles 
using catalytic (enzyme-based) and binding modes. 
Unlike in the ICU, a major emphasis in ambulatory 
medicine has been on minimally or non-invasive measure-
ments with tissue probes rather than catheter-based 
sensors. Most ambulatory systems have measured glucose 
in the interstitial space with regular calibration against a 
reference blood sample, often a capillary sample.
Numerous techniques are available for continuous 
glucose monitoring in the ICU, including microdialysis 
and optical methods such as absorption spectroscopy, 
optical scattering and ﬂ uorescence [27]. Th e blood 
glucose concentration can be measured in vitro by 
sensors that sit in the vascular or interstitial space or ex 
vivo by drawing blood samples or a dialysate to a sensor 
from an indwelling vascular catheter or dialysis mem-
brane. Systems that intermittently draw blood to an 
externally based sensor may be described as automated 
intermittent monitors rather than continuous glucose 
monitors. Potential advantages of continuous glucose 
monitors include the ability to observe trends in blood 
glucose concentration and to intervene before the blood 
glucose concentration enters an unacceptable range, and 
removal of operator error both in the timing of blood 
glucose measurements and in the sampling and analysis 
of blood.
Can we use the same measures for assessment of 
glucose control with continuous and intermittent 
monitoring?
As noted in the ﬁ rst section of this paper, almost all 
monitoring of the blood glucose concentration in 
critically ill patients is by intermittent measurement. 
Although intermittent measurement is current standard 
practice, there is no agreed metric for reporting glycemic 
control and many of the metrics currently reported are 
aﬀ ected by the frequency of measurement. Current 
systems for continuous or automated intermittent 
monitor ing may measure the blood glucose concentration 
at a frequency varying from every minute to every 
15  minutes. Such monitors will not only increase the 
number of measurements, but will also standardize the 
frequency of measurements amongst patients monitored 
with each device. Th is may allow for a better reporting of 
glucose control metrics, and if suﬃ  ciently accurate may 
oﬀ er a better understanding of the association between 
those metrics and outcomes.
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Possible metrics available from continuous glucose 
monitoring systems include the following (Figure  2 and 
Table 2):
1. Measures of central tendency:
a. Th e mean and median blood glucose per patient, 
per day and during stay in the ICU.
2. Measures of dispersion and variability:
a. Th e standard deviation and coeﬃ  cient of variation 
of blood glucose.
b. Analysis of the rate of change of the blood glucose 
concentration.
c. Th e peak blood glucose concentration reached 
within a set time period after correction of 
hypoglycemia.
3. Hypoglycemia and lowest blood glucose concentration:
a. Th e lowest blood glucose concentration recorded.
b. Th e area above the curve under the target for mild 
and severe hypoglycemia (Area   B in Figure  2, 
where the target is to keep blood glucose 
>4.0 mmol/l).
c. Th e number of times that a blood glucose 
concentration below that deﬁ ning hypoglycemia 
or severe hypoglycemia is recorded.
d. Th e duration of time that blood glucose is below 
the concentration deﬁ ning hypoglycemia or 
severe hypoglycemia.
4. Range and exposure measures:
a. Th e percentage of time the blood glucose concen-
tration is in the target range.
b. Th e percentage of time the blood glucose con cen-
tration is outside a nominated target range.
c. Th e area under the curve above the upper target 
for hyperglycemia (Area A in Figure 2, where the 
target is to keep blood glucose <10.0 mmol/l).
d. Th e area above the curve under the target for mild 
and severe hypoglycemia (Area  B in Figure  2, 
where the target is to keep blood glucose 
>4.0 mmol/l).
Th ere are currently few data to guide the choice of 
appropriate metrics for continuous glucose monitoring. 
Th ere is a need to deﬁ ne measures that are associated 
with important patient-centered outcomes such as mor-
tality and major morbidity. Th e easiest metric to deﬁ ne 
will be the incidence and severity of hypoglycemia and 
hyperglycemia; harder to deﬁ ne will be measures of 
central tendency and dispersion, because these may be 
inﬂ uenced by the frequency of measurement.
Comparing glycemic control with continuous versus 
intermittent measurement of blood glucose
Comparison of the quality of glycemic control using con-
tinuous and intermittent measurement is a crucial ﬁ rst 
step in determining whether continuous glucose monitor-
ing systems can provide tangible beneﬁ t to patients. As 
frequent knowledge of the blood glucose concentration 
has the potential to change a patient’s management, 
comparison of the glycemic control achieved with con-
tinuous versus intermittent monitoring must be evalu-
ated in a ran domized controlled trial with both groups of 
patients having a continuous monitor but the output 
from the continuous monitor masked in the control 
group where blood glucose is managed by intermittent 
Figure 2. Schematic representation of the performance of continuous blood glucose concentration. Area A, possible measure of 
hyperglycemia (when defi ned as blood glucose concentration >10.0 mmol/l). Area B, possible measure of moderate hypoglycemia (when defi ned 
as blood glucose concentration <4.0 mmol/l).
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Table 2. Metrics to report glycemic control using continuous glucose monitoring systems
1. Measures of central tendency
 a. Mean blood glucose per patient, per day of ICU stay and during whole stay in the ICU
 b. For populations of patients, the median and interquartile range of individual patient means should be reported
 c. For comparison of glycemic control achieved with intermittent measurement versus continuous measurement, two groups should be studied in a 
  randomized controlled trial, both groups should have blood glucose concentration recorded by a CGM but the output of the CGM should be masked 
  in the control group where blood glucose concentration is managed using intermittent measurement of blood glucose concentration
2. Measures of variability and dispersion
 a. Standard deviation and coeffi  cient of variation of blood glucose (for comparison of glycemic control with intermittent measurement, two groups 
  should be studied – both groups should have blood glucose concentration recorded by a CGM but the output of the CGM be masked in the group 
  where the blood glucose concentration is managed using intermittent measurement of blood glucose concentration)
 b. Peak blood glucose concentration reached within a set time period after correction of hypoglycemia
 c. Analysis of the rate of change of the blood glucose concentration
3. Hypoglycemia and lowest blood glucose concentration
 a. Lowest blood glucose concentration recorded per patient
 b. Number of times a blood glucose concentration defi ning hypoglycemia or severe hypoglycemia was recorded
 c. Area above the curve under the target for mild and severe hypoglycemia
 d. Duration of time with blood glucose below the concentration defi ning hypoglycemia or severe hypoglycemia 
4. Range and exposure measures
 a. Percentage of time the blood glucose concentration is in the target range
 b. Percentage of time the blood glucose concentration is outside a nominated target range
 c. Area under the curve above the upper target for hyperglycemia
 d. Area above the curve but under the target for mild and severe hypoglycemia
Desirable performance standards for continuous glucose monitoring systems – the meeting accepted that these were desirable performance standards that 
might not be currently achievable
There was acceptance but not complete agreement that desirable point accuracy might vary depending on whether CGMs were intended to operate alone 
and be used to adjust insulin dosing or be used to only as a warning system to advise clinicians when to check blood glucose on a reference system
1. Desirable features with regard to set-up, calibration and integration with standard ICU care
 a. <20 minutes to set by a nurse, technician, or physician
 b. <10 minutes required for initial and subsequent calibration
 c. <20 minutes required for sensor insertion
 d. Calibration against a reference standard to maintain point accuracy is required no more frequently than every 8 hours and preferably no more than 
  twice per 24 hours
 e. CGM requires few nursing interventions per 24 hours to produce a near-continuous glucose datastream
 f. CGM sensor inserted into an arterial or central venous catheter should not adversely aff ect blood sampling or monitoring of cardiovascular system or 
  increase the frequency with which such monitoring lines occlude
 g. Incidence infection, hematoma, tissue ischemia, and/or thromboembolism should not exceed that which occurs in usual clinical practice in the 
  absence of a CGM
2. Desirable reliability
 a. CGM should continuously measure glucose and display in real time >95% of the time for the duration of time specifi ed in the product label 
  (2 to 7 days)
 b. Skips in data acquisition due to system faults or failures should not exceed 30 minutes at a time (data may be missing for other reasons; for example, 
  patient transports)
 c. The CGM should have an internal mechanism that prevents the display or reporting of erroneous or spurious data
3, Desirable point accuracy – this should be the same as for intermittent monitors if the CGM is being used alone to guide clinical management and 
 administration of insulin
 a. 98% of readings should be within 12.5% of a reference standard (or within 0.55 mmol/l for readings <5.5 mmol/l; the remaining 2% of readings should 
  be within 20% of a reference standard)
 b. CGM sensors inserted in arterial and central venous catheters may transiently indicate false low readings when those catheters are fl ushed with saline 
  or other glucose-free solutions. The CGM should alert the treating clinicians that rapid reductions in the measured blood glucose concentration may 
  be due to fl ushing of the arterial or central venous catheter
 c. CGM sensors inserted in peripheral and central veins may transiently indicate false high readings if venous blood in those veins is contaminated with 
  glucose-containing solutions. The CGM should alert the treating clinicians to rapid increases in the measured blood glucose concentration that may 
  be due to contamination by glucose-containing solutions
4. Rate or trend accuracy – CGMs should be carefully characterized in the intended-use critical care patient population to ensure point accuracy over a wide 
 range of blood glucose rates of change. Rate or trend metrics have not been tested suffi  ciently to provide defi nitive guidance 
5. Alarms and alerts for hypoglycemia and hyperglycemia alerts
 a. Real-time blood glucose concentration and trend data should be displayed at the bedside; with visual and audible alerts and alarms for hypoglycemia, 
  hyperglycemia, and rapid rates of change
 b. The CGM data should be suffi  ciently frequent, reliable, and accurate for alarm algorithms to detect and/or predict hypoglycemia and hyperglycemia 
  with high sensitivity and specifi city
The meeting recognized that further research is needed to determine which of these metrics are closely associated with mortality and major morbidity when 
continuous or automated intermittent glucose monitoring systems (CGMs) are used.
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monitoring. Th is will be the only way to accurately 
compare the relative eﬀ ect of continuous versus inter-
mittent monitoring on glycemic control.
What are acceptable performance standards for 
continuous glucose monitoring systems? (Table 1)
Continuous or automated intermittent glucose monitor-
ing systems (CGMs) should safely and reliably provide an 
accurate interstitial ﬂ uid or blood glucose measurement 
every 1 to 15  minutes. Th ey should maintain their 
accuracy for a period of days and over a wide range of 
glucose values, rates of change of blood glucose concen-
tration, and patient conditions. Each CGM should 
demon strate accuracy in the intended-use critical care 
population to ensure safety. Point accuracy  – the accu-
racy with which each static blood glucose measurement 
matches a reference measurement – should be similar to 
that required of intermittent monitoring systems. Rate or 
trend accuracy  – the accuracy with which the CGM is 
able to track changes in blood glucose concentration – is 
a speciﬁ c feature of continuous glucose monitoring 
systems and standards have yet to be developed. 
Standards for rate accuracy may diﬀ er if CGMs are 
intended only to warn clinicians that blood glucose is 
trending out of range and changes in management are 
not made until the CGM reading is conﬁ rmed by a 
reference blood glucose measurement. Greater accuracy 
is required if the CGM readings are to be used to guide 
therapy, in particular the administration of insulin, with-
out conﬁ rmation from a reference blood glucose measure-
ment. CGMs must also demonstrate a lack of interference 
from substances other than glucose, and a lack of sample 
contamination by adjacent infusions.
Th e set-up and calibration of the CGM should be easy 
to perform in the clinical setting using methods that 
provide an accurate reference blood glucose measure-
ment; and the CGM should withhold data and alert the 
clinician when accuracy becomes questionable. Th e 
current glucose concen tration and trend data should be 
displayed at the bedside, with visual and audible alerts 
and alarms for hypo gly cemia, hyperglycemia, and rapid 
rates of change. Th e CGM data should be suﬃ  ciently 
frequent, reliable, and accurate for alarm algorithms to 
detect and/or predict hypoglycemia and hyperglycemia 
with high sensitivity and speciﬁ city.
All systems (needle-type CGM sensors inserted into 
the subcutaneous tissue that provide an interstitial ﬂ uid 
glucose measurement, optical ﬁ ber and dialysis catheter 
CGM sensors inserted directly into the bloodstream, and 
external CGM sensors attached to a vascular catheter) 
should ideally provide a glucose measurement that agrees 
closely with the true blood glucose concentration when 
recalibrated less than three times per day. Additional 
studies are required to determine whether adjacent 
infusions aﬀ ect CGM performance when attached to a 
central venous catheter.
Insuﬃ  cient data currently exist for most systems to 
demonstrate that they can meet these performance 
standards in a broad range of critical care settings.
Conclusion
In view of the lack of standardization in the management, 
reporting and assessment of glycemic control, we realized 
that recommendations were needed for the use of 
diﬀ erent methods to measure the blood glucose concen-
tration and for the report of the performance of insulin 
treatment. We suggest in this review ways to report the 
central tendency, dispersion and rate of hypoglycemia 
when intermittent and continuous blood glucose values 
are reported. We also suggest minimal performance 
standards for intermittent and continuous blood glucose 
monitors when these are used in ICUs. We thereby hope 
to improve glycemic control in daily clinical practice and 
to minimize the disparities and to facilitate the 
interpretation and comparison of clinical trials.
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